Sanofi SA SNYNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNYNF is a good fit for your portfolio.
News
-
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial
-
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
-
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
-
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in COPD
-
Sanofi Proposes Appointment of New Independent Directors
-
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint
-
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk
-
Sanofi Taps Nestle's Roger as CFO After Swing to Net Loss
Trading Information
- Previous Close Price
- $92.70
- Day Range
- $94.25–94.25
- 52-Week Range
- $86.12–114.90
- Bid/Ask
- $91.15 / $96.14
- Market Cap
- $117.65 Bil
- Volume/Avg
- 482 / 82,607
Key Statistics
- Price/Earnings (Normalized)
- 9.76
- Price/Sales
- 2.32
- Dividend Yield (Trailing)
- 4.11%
- Dividend Yield (Forward)
- 4.38%
- Total Yield
- 4.48%
Company Profile
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 87,994
- Website
- https://www.sanofi.com
Competitors
Valuation
|
Metric
|
SNYNF
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.76 | 13.97 | 84.62 |
Price/Book Value | 1.52 | 4.17 | 8.55 |
Price/Sales | 2.32 | 4.26 | 5.38 |
Price/Cash Flow | 11.34 | 13.64 | 21.26 |
Price/Earnings
SNYNF
NVS
MRK
Financial Strength
|
Metric
|
SNYNF
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.83 | 0.88 | 0.68 |
Current Ratio | 1.27 | 1.16 | 1.25 |
Interest Coverage | 11.03 | 10.94 | 2.33 |
Quick Ratio
SNYNF
NVS
MRK
Profitability
|
Metric
|
SNYNF
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 8.05% | 12.15% | 3.59% |
Return on Equity (Normalized) | 14.38% | 27.10% | 9.12% |
Return on Invested Capital (Normalized) | 10.85% | 17.72% | 5.88% |
Return on Assets
SNYNF
NVS
MRK
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Mbtftscgsh | Pkh | $695.3 Bil | |
JNJ
| Johnson & Johnson | Dpfppbwjb | Hvkc | $359.3 Bil | |
MRK
| Merck & Co Inc | Yngccccs | Rlqb | $321.5 Bil | |
ABBV
| AbbVie Inc | Dbmbzsxzh | Wvnj | $297.3 Bil | |
AZN
| AstraZeneca PLC ADR | Nnphkytrj | Dqkyk | $215.8 Bil | |
RHHBY
| Roche Holding AG ADR | Qybrpphdj | Ckhz | $199.7 Bil | |
NVS
| Novartis AG ADR | Czywjgd | Sgqw | $196.0 Bil | |
PFE
| Pfizer Inc | Chwsfntqc | Svytv | $148.7 Bil | |
AMGN
| Amgen Inc | Djhghvlqm | Bpmcf | $145.8 Bil | |
SNY
| Sanofi SA ADR | Kqnbtfm | Kqvz | $117.3 Bil |